Nature walks vs. treadmills: green exercise shows promise for schizophrenia
NCT ID NCT07058389
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether physical activity in green outdoor spaces reduces negative symptoms (like lack of motivation or social withdrawal) in people with schizophrenia more than indoor exercise. 45 adults aged 18-55 with persistent negative symptoms will participate. Researchers will compare changes in symptom severity between the two groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with schizophrenia, aged 18 to 55 years * Having persistent negative symptoms (SNS), negative symptoms self-assessment scale \> 7 * Regularly monitored in the psychiatry department. * Have no medical contraindications to physical activity * Subject affiliated with or entitled to a social security system. * Subject having received informed information about the study and having co-signed, with the investigator, consent to participate in the study. * Male or female. Exclusion Criteria: * Patient unsuitable for study in the opinion of the investigator * Any subject with chronic joint pathologies (example: repeated sprains, patellar or ligament problems) or cardiac pathologies. * Any subject presenting chronic or central neurological pathologies. * Any subject deprived of liberty or subject to legal protection * Excessive consumption of alcohol (\> 14 glasses per week) or caffeinated drinks (\> 400 mg of coffee per day). * Pregnant women. * Subject unable to understand the purpose and conditions of the study, unable to give consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Saint-Etienne
RECRUITINGSaint-Etienne, France, 42055, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug